A Phase 3 clinical trial called Illuminate 301, NCT03445533, is now recruiting patients with advanced melanoma that has not responded to available FDA-approved treatments. Illuminate 301 will evaluate the safety and effectiveness of an investigational study drug called Tilsotolimod (IMO-2125) in combination with an FDA-approved immunotherapy drug called Yervoy® (ipilimumab) compared to Yervoy® given by itself in patients who have refractory melanoma. For more information about the trial, please visit https://clinicaltrials.gov/ct2/show/NCT03445533.”
Viewing 1 post (of 1 total)
The forum ‘Newly Diagnosed Stage III/IV’ is closed to new topics and replies.